As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with BioMarin Pharmaceutical (NASDAQ:BMRN).

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is expanding its rare-disease business with the acquisition of Alesta Therapeutics for $275 million upfront. The deal gives BioMarin access to ALE1, an oral treatment being developed for hypophosphatasia (HPP), a rare genetic bone disorder. ALE1 is still in early-stage clinical trials, so there is a long way to go before […]

The deal gives BioMarin access to ALE1, a small-molecule drug in early-stage trials that could become the first oral therapy for hypophosphatasia

The deal provides BioMarin with a potential rival to AstraZeneca’s blockbuster Strensiq in hypophosphatasia.

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.

Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that traders need to see before the open.

BioMarin said that it would acquire Alesta for $275M upfront and up to $215M in development and regulatory milestones to bring ALE1 into its portfolio.

BioMarin Pharmaceutical's (BMRN) Alesta acquisition adds a new pipeline opportunity and supports lon

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares climbed 4.

The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatments in development.

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a US$719.24 million common stock shelf registration for an ESOP-related offering, highlighting how management is pairing refined guidance with expanded equity issuance capacity. Now...

BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the year, and a new shelf registration filing. See our latest analysis for BioMarin Pharmaceutical. At a share price of US$67.36, BioMarin Pharmaceutical has seen a 90-day share price return of 35.62% and a 1-year total shareholder return of 17.07%, although the 3-year total shareholder return is down 24.36%. This points to improving short...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Five stocks stand out as potentially undervalued by price-to-book measures, including BioMarin Pharmaceutical, Invesco and Centene.

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a "Buy" rating.

BioMarin Pharmaceutical (NASDAQ:BMRN) outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller. Mueller described BioMarin as one of the largest rare-disease-focused biopharmaceutical com

The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.

BioMarin Pharmaceutical's (BMRN) Q2 Voxzogo sales exceeded expectations, and the company raised its

BioMarin Pharmaceutical stock has edged up only modestly in the past year after a much weaker three year stretch, and the current valuation checks suggest investors are paying a premium for that recovery. The share price is down 32.4% over the past 3 years, which points to a difficult period for long term holders even with a recent stabilisation. The new collaboration with the n-Lorem Foundation on an antisense therapy for ReNU syndrome may support sentiment if it progresses well. At the...

BioMarin delivers 20% revenue growth and raises guidance amid successful Amicus integration and strong VOXZOGO performance.

BioMarin Pharmaceutical (NASDAQ:BMRN) reported second-quarter 2026 revenue of nearly $1 billion, up 20% from a year earlier, as growth across its rare-disease portfolio and the recently completed Amicus acquisition supported results. The company raised its full-year revenue, VOXZOGO revenue and non-

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 19.9% year on year to $989.7 million. The company’s full-year revenue guidance of $3.9 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $1.20 per share was 26.6% above analysts’ consensus estimates.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin and n-Lorem will carry out preclinical studies and jointly select a lead candidate for trials.

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical trades at $59.99 per share and has stayed right on track with the overall market, gaining 6.5% over the last six months. At the same time, the S&P 500 has returned 11.4%.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

BioMarin Pharmaceutical (BMRN) stock is back in focus after the FDA accepted the company’s supplemental New Drug Application for VOXZOGO, with a target decision date set for February 28, 2027. See our latest analysis for BioMarin Pharmaceutical. BioMarin Pharmaceutical’s recent FDA filing comes after a period where momentum has picked up, with a 30 day share price return of 5.81% and a 90 day share price return of 6.72%, although the 3 year total shareholder return is still down 31.69%. If...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.